Summary
The effectiveness of Synthetic Salmon Calcitonin (SSCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 5 Pagetic patients during a 6 months course therapy, the results show that intranasal administration does not decrease the activity of SSCT in Paget's disease of bone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Meunier PJ (1975) La maladie de Paget. Histologie quantative et prescriptions therapeutiques. Lyon Med 233: 839–853
Fournier A (1975) Traitment de la maladie de Paget par la Calcitonine. Rev Med Toulouse 11: 655–684
Gennari C, Cecchetin M, Passeri M, Francini G, Gonelli S, Nami R, Bigazzi S (1983) Gli effetti collaterali di differenti Calcitonine. In: Gennari C, Segre G (eds) Calcitonin in man. Masson, Milano, pp 93–101
Trayser KA, Seligson D (1969) A new kinetic method for enzyme analysis suitable for automation. Clin Chem 15: 452
Zerbe GO (1979) Randomization analysis of the completely randomized design extended to growth and response curves. JASA 74: 215–221
Dietrich FM, Fischer JA (1977) Immunological studies with synthetic human Calcitonin. In: MacIntyre I (eds) Human calcitonin and Paget's disease. Hans Huber Publishers, Bern, Stuttgart. Vienna, pp 179–194
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reginster, J.Y., Albert, A. & Franchimont, P. Salmon-calcitonin nasal spray in Paget's disease of bone: Preliminary results in five patients. Calcif Tissue Int 37, 577–580 (1985). https://doi.org/10.1007/BF02554908
Issue Date:
DOI: https://doi.org/10.1007/BF02554908